SOLV vs VRTX: fair value comparison
Solventum Corporation and Vertex Pharmaceuticals Incorporated · Updated 2026-09-06
SOLV currently screens as overvalued while VRTX screens as fairly valued. Within Healthcare, VRTX currently sits closer to the top of our discount ranking. VRTX carries the stronger quality grade.
| SOLV | VRTX | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $91.69 | $546.12 |
| 12-month range | $64.35–$90.95 | $423.92–$547.65 |
| Sector rank | #87 of 113 Healthcare | #82 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | High | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: SOLV fair value analysis · VRTX fair value analysis